Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H ( (HK:2591) ) has provided an update.
Guangzhou Innogen Pharmaceutical Group Co., Ltd. announced that its subsidiary, Innogen Technology, subscribed to a CMB Structured Deposit Product from China Merchants Bank for RMB30,000,000, utilizing internal funds. This transaction, along with previous Pre-IPO subscriptions, totals RMB105,000,000 in structured deposit products. Additionally, the company and its subsidiary subscribed to a Ningbo Structured Deposit Product from the Bank of Ningbo for RMB105,000,000. These investments are part of the company’s treasury management strategy, leveraging surplus cash for potential returns.
More about Guangzhou Innogen Pharmaceutical Group Co Ltd Class H
Guangzhou Innogen Pharmaceutical Group Co., Ltd. is a pharmaceutical company based in China, focusing on the development and production of pharmaceutical products. It operates within the healthcare industry, providing a range of pharmaceutical solutions.
Average Trading Volume: 2,429,517
For an in-depth examination of 2591 stock, go to TipRanks’ Overview page.
Trending Articles:
- “…Overlook a Lack of Earnings Power”: UBS Analysts Target Intel Stock (NASDAQ:INTC), Stock Gains
- “…Significantly Extend the Reach and Lethality of our Fleet”: Boeing Stock (NYSE:BA) Slips Despite Successful MQ-25A Test
- “Direct Result of Your Feedback….” Microsoft Stock (NASDAQ:MSFT) Slips as The Option to Skip Updates Emerges